quantisnow
FeedTopReportsPricing
⌘K
Live feed
13:09:00·2d
PRRelease
Corcept Therapeutics Incorporated logo

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

CORT· Corcept Therapeutics Incorporated
Health Care
Original source

Companies

  • CORT
    Corcept Therapeutics Incorporated
    Health Care

Recent analyst ratings

  • Mar 26UpdateWolfe Research-
  • Dec 31UpdateWolfe Research$30.00
  • Dec 16UpdateUBS-
  • Nov 18UpdateWolfe Research-
  • Nov 6UpdateTruist$38.00
  • Apr 11UpdateSVB Securities$25.00

Related

  • PR10h
    Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
  • SEC2d
    Amendment: SEC Form SCHEDULE 13G/A filed by Corcept Therapeutics Incorporated
  • SEC6d
    SEC Form DEF 14A filed by Corcept Therapeutics Incorporated
  • PR13d
    Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
  • INSIDER15d
    SEC Form 4 filed by Guyer William
  • INSIDER15d
    SEC Form 4 filed by Wilson James N
  • PR26d
    Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
  • INSIDER27d
    SEC Form 4 filed by Belanoff Joseph K
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022